AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28187125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76
Study 25879905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation intervention
Number of subjects: 30
Study 25879905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component sit-stand workstation intervention
Number of subjects: 30
Study 25879905 — intervention group
Group type: COMPARATOR
Intervention: Usual desk use (control)
Number of subjects: 30
Study 23949032 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG Biofeedback (EMG BF), Traditional Rehabilitation and Gait Training
Number of subjects: 30
Study 23949032 — intervention group
Group type: COMPARATOR
Intervention: Traditional Rehabilitation and Gait Training
Number of subjects: 30
Study 22099891 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 71
Study 22099891 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen combined with 1000 mg acetaminophen
Number of subjects: 71
Study 22099891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 71
Study 19662384 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 0
Study 19662384 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg)
Number of subjects: 0
Study 19662384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (prior to escitalopram)
Number of subjects: 0
Study 17893578 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine
Number of subjects: 24
Study 17893578 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 24
Study 16764041 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate as a vehicle for nebulized salbutamol
Number of subjects: 219
Study 16764041 — intervention group
Group type: COMPARATOR
Intervention: Saline as a vehicle for nebulized salbutamol
Number of subjects: 219
Study 16764041 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate in severe asthma patients
Number of subjects: 219
Study 12701547 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (41 cohorts, 8,885 subjects)
Number of subjects: 18922
Study 12701547 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions (22 cohorts, 6,392 subjects)
Number of subjects: 18922
Study 12701547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (32 cohorts, 3,645 subjects)
Number of subjects: 18922
Study 12701547 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence increase
Number of subjects: 18922
Study 10618930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 MAC of sevoflurane
Number of subjects: 10
Study 10618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hypercapnia
Number of subjects: 10
Study 7496445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 10 micrograms
Number of subjects: 283
Study 7496445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 20 micrograms
Number of subjects: 283
Study 7496445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 30 micrograms
Number of subjects: 283
Study 1780425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 24
Study 1780425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7019840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (administered for 12 hours)
Number of subjects: 10
Study 7019840 — intervention group
Group type: COMPARATOR
Intervention: Control (no pancuronium bromide, administered for 12 hours)
Number of subjects: 10
Study 29679106 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week social support program
Number of subjects: 120
Study 29679106 — intervention group
Group type: COMPARATOR
Intervention: Single mental health awareness session
Number of subjects: 120
Study 27221398 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (up to 12 mg/day)
Number of subjects: 133
Study 27221398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 27221398 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 133
Study 23976778 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 23
Study 23976778 — intervention group
Group type: COMPARATOR
Intervention: Sham-device
Number of subjects: 23
Study 22704741 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA+feedback (FB)
Number of subjects: 210
Study 22704741 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 210
Study 22704741 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 210
Study 22704741 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (adherence comparison)
Number of subjects: 210
Study 22704741 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA and PDA+FB groups
Number of subjects: 210
Study 22704741 — intervention group
Group type: COMPARATOR
Intervention: Combined PDA groups vs. paper diary group
Number of subjects: 210
Study 19936588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (Nazca R, Promedon, Cordoba, Argentina)
Number of subjects: 32
Study 19936588 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation
Number of subjects: 32
Study 19936588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 32
Study 18318706 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth positioner (group I)
Number of subjects: 16
Study 18318706 — intervention group
Group type: COMPARATOR
Intervention: Hawley's appliance (group II)
Number of subjects: 16
Study 15922309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 32
Study 15922309 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 32
Study 11829455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile38 variant of hBD-1
Number of subjects: 273
Study 11829455 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals without Ile38 variant
Number of subjects: 273
Study 10367725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (300 mg x kg(‐1) body mass)
Number of subjects: 10
Study 10367725 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study 10367725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 7731149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnic hypobicarbonatemic hyperventilation at 18 or 36 liter/min
Number of subjects: 0
Study 7731149 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery post-hyperventilation
Number of subjects: 0
Study 7731149 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenoreceptor blockade (timolol)
Number of subjects: 0
Study 7731149 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoreceptor blockade (phentolamine)
Number of subjects: 0
Study 7731149 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic and isobicarbonatemic hypocapnic hyperventilation
Number of subjects: 0
Study 2200896 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg.kg‐1
Number of subjects: 12
Study 2200896 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal 4 mg.kg‐1
Number of subjects: 12
Study 7243973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eyelid incision
Number of subjects: 0
Study 7243973 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital rim incision
Number of subjects: 0
Study 7243973 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival incision
Number of subjects: 0
Study 7243973 — intervention group
Group type: COMPARATOR
Intervention: Subciliary incision
Number of subjects: 0
Study 7243973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral canthotomy
Number of subjects: 0
Study 30661058 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based education (PE)
Number of subjects: 60
Study 30661058 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 60
Study 29045769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 29045769 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drugs (olanzapine, quetiapine, risperidone)
Number of subjects: 371
Study 26464455 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (40 mg) with alcohol (0.7 g/kg)
Number of subjects: 31
Study 26464455 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (40 mg) alone
Number of subjects: 31
Study 26464455 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg) alone
Number of subjects: 31
Study 26464455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23261493 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200mg NAC twice daily)
Number of subjects: 89
Study 23261493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 21876071 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/d
Number of subjects: 54
Study 21876071 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 160 mg/d
Number of subjects: 54
Study 21876071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18611293 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication augmentation
Number of subjects: 1286
Study 18611293 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch
Number of subjects: 1286
Study 17156300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eye drops
Number of subjects: 0
Study 17156300 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 0
Study 14588176 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (pulses and egg-rich diet)
Number of subjects: 61
Study 14588176 — intervention group
Group type: COMPARATOR
Intervention: Diet 1 (vegetables and milk-rich diet)
Number of subjects: 61
Study 10764366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner care
Number of subjects: 1368
Study 10764366 — intervention group
Group type: COMPARATOR
Intervention: General Practitioner care
Number of subjects: 1368
Study 8623731 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 8623731 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829
Study 8623731 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829
Study 8623731 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 1618258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 12
Study 1618258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg
Number of subjects: 12
Study 1618258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6375889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg qid)
Number of subjects: 14
Study 6375889 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg qid)
Number of subjects: 14
Study 6375889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg qid) + Captopril (25 mg qid)
Number of subjects: 14
Study 6375889 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 31373563 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling as needed for 12 weeks post-surgery
Number of subjects: 70
Study 31373563 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient follow-up care only for 12 weeks post-surgery
Number of subjects: 70
Study 28013557 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light nutritional labeling system awareness and comprehension among indigenous women
Number of subjects: 394
Study 28013557 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light nutritional labeling system awareness and comprehension among mestiza women
Number of subjects: 394
Study 28013557 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of nutrition labels
Number of subjects: 394
Study 28013557 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nutrition labels for food choices among mestiza women
Number of subjects: 394
Study 28013557 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nutrition labels for food choices among indigenous women
Number of subjects: 394
Study 25491500 — intervention group
Group type: EXPERIMENTAL
Intervention: School meals rich in fish, vegetables and fibre
Number of subjects: 797
Study 25491500 — intervention group
Group type: COMPARATOR
Intervention: Usual packed lunch (control)
Number of subjects: 797
Study 24064970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-radiotherapy with erlotinib
Number of subjects: 204
Study 21968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Active product (Souvenaid)
Number of subjects: 319
Study 21968871 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 319
Study 21968871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 319
Study 19295325 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg)
Number of subjects: 68
Study 19295325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16713921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (90 g total, infused over 3 consecutive days, repeated after 3 months)
Number of subjects: 135
Study 16713921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 135
Study 16713921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA indices in symptomatic patients
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA indices in APC patients
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA indices in TCPC patients
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA indices
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA indices post-surgery
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA and CANA correlation
Number of subjects: 97
Study 15492308 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA and CANA indices by age and morphology
Number of subjects: 97
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 mRNA in stenotic specimens
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1/CD31 ratio
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin gene expression in obstructed junctions
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to GAPDH
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to CD31
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to smooth muscle alpha-actin
Number of subjects: 20
Study 11350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-actin mRNA in stenotic tissues
Number of subjects: 20
Study 9419295 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISC
Number of subjects: 50
Study 9419295 — intervention group
Group type: COMPARATOR
Intervention: -ISC
Number of subjects: 50
Study 10172484 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 162
Study 10172484 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study 2628131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg orally twice daily for 10 days
Number of subjects: 160
Study 2628131 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 250 mg orally three times daily for 10 days
Number of subjects: 160
Study 2628131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil for acute on chronic sinusitis
Number of subjects: 160
Study 2628131 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin for acute on chronic sinusitis
Number of subjects: 160
Study 786190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DMP)
Number of subjects: 500
Study 786190 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS)
Number of subjects: 500
Study 786190 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-treated group (DMP + MPS)
Number of subjects: 500
Study 786190 — intervention group
Group type: COMPARATOR
Intervention: Control group (Saline)
Number of subjects: 500
Study 786190 — intervention group
Group type: COMPARATOR
Intervention: Control group (No steroid)
Number of subjects: 500
Study 786190 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-treated patients (DMP + MPS)
Number of subjects: 500
Study 31232076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + prehabilitation (nutritional support, control of diabetes and exocrine pancreatic insufficiency, physical and respiratory training)
Number of subjects: 40
Study 31232076 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 28486086 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing-distance interval-training (100-200-300-400-500 m)
Number of subjects: 40
Study 28486086 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing-distance interval-training (500-400-300-200-100 m)
Number of subjects: 40
Study 28486086 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing-distance interval-training
Number of subjects: 40
Study 28486086 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing-distance interval-training
Number of subjects: 40
Study 25890135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 16
Study 25890135 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision training
Number of subjects: 16
Study 23497981 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg/kg atomized dexmedetomidine
Number of subjects: 18
Study 23497981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal water)
Number of subjects: 18
Study 21570054 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CsA) administered for at least 6 months with a blood CsA concentration of approximately 800 ng/mL.
Number of subjects: 39
Study 21570054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systemic cyclosporine).
Number of subjects: 39
Study 21570054 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CsA) administered for at least 6 months.
Number of subjects: 39
Study 19232638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Environment (SAE)
Number of subjects: 35
Study 17042889 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine (15 mg/kg/day)
Number of subjects: 60
Study 17042889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17042889 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 60
Study 12601631 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (3 years treatment)
Number of subjects: 25
Study 12601631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study 10604887 — intervention group
Group type: EXPERIMENTAL
Intervention: h5G1.1‐scFv at 2 mg/kg
Number of subjects: 0
Study 10604887 — intervention group
Group type: EXPERIMENTAL
Intervention: h5G1.1‐scFv at 1 or 2 mg/kg
Number of subjects: 0
Study 8542173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 8542173 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and primary medical treatment
Number of subjects: 0
Study 1834835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized, regenerated cellulose absorbable adhesion barrier
Number of subjects: 80
Study 6453908 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 14
Study 6453908 — intervention group
Group type: COMPARATOR
Intervention: Not treated with BCG
Number of subjects: 14
Study 6453908 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 14
Study 6453908 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 14
Study 6140091 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol (40 to 120 mg/day)
Number of subjects: 16
Study 30936290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment
Number of subjects: 0
Study 29482672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully slatted flooring (CS)
Number of subjects: 80
Study 29482672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully slatted flooring covered with rubber strips (RS)
Number of subjects: 80
Study 29482672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully slatted flooring during growing period and solid floor covered with straw bedding during finishing period (CS-S)
Number of subjects: 80
Study 29482672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully slatted flooring during growing period and fully slatted flooring covered with rubber strips during finishing period (CS-RS)
Number of subjects: 80
Study 29482672 — intervention group
Group type: COMPARATOR
Intervention: Control group (RS)
Number of subjects: 80
Study 29482672 — intervention group
Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 80
Study 27253214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) - 10 weekly sessions followed by 8 booster sessions over 2 years
Number of subjects: 85
Study 27253214 — intervention group
Group type: COMPARATOR
Intervention: Individual psychoeducation (IP) - 3 sessions
Number of subjects: 85
Study 27253214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) with comorbid harmful substance use (HSU)
Number of subjects: 85
Study 27253214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP) without harmful substance use (HSU)
Number of subjects: 85